Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer

Nature Reviews Urology, Published online: 28 June 2021; doi:10.1038/s41585-021-00483-zDespite the success of immune checkpoint inhibition (ICI) in other tumour types, the majority of ICI-treated patients with bladder cancer fail to respond. This lack of efficacy might be attributable to a lack of pre-existing immune reactive cells within the tumour immune microenvironment, which limits the efficacy of ICI. In this Review, Li and colleagues discuss how oncolytic virus therapy acts as a strategy to attract lymphocytes before implementation of ICI and consider the data supporting the use of combination approaches using oncolytic virotherapy with ICI in bladder cancer.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research